Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
Executive Summary
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
You may also be interested in...
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
GIFT Does Damage To Idea Of Double Dosing Of Plavix For Poor Responders
Increasing the dose of Plavix (clopidogrel) does not seem to be a sufficient strategy for treating patients who are poor metabolizers of the soon-to-be generic drug, according to a new trial of genetic testing for responders and contrary to a small study currently in labeling of the Bristol-Myers Squibb/Sanofi-Aventis drug.